Lipid kinase regulation of pain signaling and sensitization
Lipid kinase regulation of pain signaling and sensitization
批准号:
9279273
负责人:
Mark J. Zylka
金额:
$32.99万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2018-05-31
关键词:
AVIL geneAcute PainAdultAdverse effectsAfferent NeuronsAnalgesicsBehavioralBiochemicalBradykininBrainBypassChemicalsComplexDataDependenceDevelopmentEnzymesFutureG-Protein-Coupled ReceptorsGoldHumanHydrolysisHypersensitivityIndividualInflammationInflammatoryIon ChannelKnockout MiceLeadLipidsMaintenanceMedicalMembraneModelingMolecularMusNerve Growth FactorsNeuronsNociceptionOpioidPainPathway interactionsPharmaceutical PreparationsPhenotypePhosphatidylinositol 4,5-DiphosphatePhosphatidylinositolsPhosphotransferasesProcessPropertyReceptor ActivationReceptor Protein-Tyrosine KinasesReceptor SignalingRegulationResearchSecond Messenger SystemsSignal PathwaySignal TransductionSpinal GangliaStimulusStructure of trigeminal ganglionTRP channelTamoxifenTestingThermal HyperalgesiasTimeTissuesbasechronic paincommon symptomeffective therapyexperimental studygenetic approachin vivoinflammatory paininhibitor/antagonistinnovationknock-downlysophosphatidic acidmechanical allodyniamouse modelnerve injurynociceptive responsenovelnovel strategiespain symptompainful neuropathyphosphatidylinositol 4-phosphatepublic health relevancereceptorreduce symptomsresponsespontaneous pain
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): New approaches for treating chronic pain are needed, particularly since existing analgesics have serious side effects and are not always effective at treating inflammatory pain and neuropathic pain-the two most common forms of chronic pain in humans. Inflammation and nerve injury lead to the release of a complex mix of chemicals that signal through molecularly diverse pronociceptive (pain-producing) receptors. Activation of these receptors increases the excitability and sensitivity of nociceptive dorsal root
ganglia (DRG) and trigeminal ganglia neurons. Unfortunately, efforts to block individual pronociceptive receptors have so far failed to produce effective treatments for chronic pain. Here, we propose an innovative approach to reduce pain hypersensitivity that bypasses this long-standing problem associated with receptor diversity. Our approach is based on selectively reducing the level of the lipid second messenger phosphatidylinositol 4,5- bisphosphate (PIP2) in DRG neurons. Most pronociceptive receptors require PIP2 to initiate downstream signaling. Moreover, many TRP channels that detect noxious stimuli and ion channels that regulate membrane excitability require PIP2 for activity. PIP2 thus sits at a key convergence point for diverse receptors, ion channels and signaling pathways that promote and maintain chronic pain. In preliminary studies with mice, we identified a lipid kinase that generates at least 50% of all PIP2 in DRG neurons. Moreover, inactivation of this lipid kinase profoundly reduced nociceptive sensitization in response to an inflammatory agent. Based on our preliminary data, we hypothesize that this lipid kinase acts through PIP2 dependent mechanisms to regulate pronociceptive receptor signaling in DRG neurons and pain sensitization in vivo. To test this hypothesis we will: 1. Evaluate the extent to which this lipid kinase regulates nociceptive sensitization in vivo, using mouse models of acute, chronic and spontaneous pain, including models of inflammatory pain and neuropathic pain. We will use an innovative genetic approach to knock-down kinase activity. This approach selectively reduces PIP2 concentration in DRG but does not affect PIP2 concentration in other tissues that process pain signals. We will further evaluate PIP2-dependence using biochemical rescue experiments. 2. Evaluate the extent to which this kinase regulates signaling through diverse pronociceptive receptors, including G protein-coupled receptors, a tyrosine kinase receptor, and TRP channels that detect noxious stimuli. 3. Utilize a new conditional knockout mouse to inducibly delete this kinase only in sensory neurons of adults and to evaluate the extent to which this kinase regulates initiation and maintenance of inflammatory pain and neuropathic pain. We will be the first to rigorously study the importance of this kinase in the setting of chronic pain. Our preliminary data suggest this lipid kinase is a master regulator of pain signaling and sensitization.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Conditional deletion of Pip5k1c in sensory ganglia and effects on nociception and inflammatory sensitization.
感觉神经节中 Pip5k1c 的条件性缺失及其对伤害感受和炎症敏化的影响。
DOI:
10.1177/1744806917737907
发表时间:
2017
期刊:
Molecular pain
影响因子:
3.3
作者:
[Loo,Lipin, Zylka,Mark]
通讯作者:
Zylka,Mark
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10094266
-
项目类别:
-
资助金额:$36.22万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10579988
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10717670
-
项目类别:
-
资助金额:$3.97万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10349447
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
CRISPR/Cas9-based gene therapy for Angelman syndrome
-
批准号:10490828
-
项目类别:
-
资助金额:$54.07万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
-
批准号:10402265
-
项目类别:
-
资助金额:$85.2万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
CRISPR/Cas9-based gene therapy for Angelman syndrome
-
批准号:10237150
-
项目类别:
-
资助金额:$58.61万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
-
批准号:10618242
-
项目类别:
-
资助金额:$85.2万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
CRISPR/Cas9-based gene therapy for Angelman syndrome
-
批准号:10011898
-
项目类别:
-
资助金额:$56.99万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
Identification of candidate environmental risks for autism
-
批准号:9525549
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2017
-
负责人:Mark J. Zylka
-
依托单位:
The Elongation Hypothesis of Autism
-
批准号:8899547
-
项目类别:
-
资助金额:$76.0万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
Lipid kinase regulation of pain signaling and sensitization
-
批准号:8627903
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
The Elongation Hypothesis of Autism
-
批准号:8560195
-
项目类别:
-
资助金额:$76.0万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
Lipid kinase regulation of pain signaling and sensitization
-
批准号:8723315
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:7763510
-
项目类别:
-
资助金额:$71.68万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:8541896
-
项目类别:
-
资助金额:$70.82万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:8144264
-
项目类别:
-
资助金额:$73.05万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:8332859
-
项目类别:
-
资助金额:$73.03万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
BAC Technology
-
批准号:7620183
-
项目类别:
-
资助金额:$18.59万
-
财政年份:2008
-
负责人:Mark J. Zylka
-
依托单位:
Biochemical Modulation of Nociceptive Circuits
-
批准号:7347513
-
项目类别:
-
资助金额:$31.71万
-
财政年份:2007
-
负责人:Mark J. Zylka
-
依托单位:
海外基金